In the world of cancer therapeutics, transcription factors have long represented the ultimate challenge – critical drivers of disease, which have stubbornly resisted conventional drug discovery approaches.

At AACR 2025, an innovative US-based biotech revealed an elegant solution to one such notorious target: a molecular glue capable of hijacking natural cellular machinery to overcome what many considered impossible.

Their approach not only demonstrates a path forward for historically intractable targets, it also reminds us how in science, persistence and creative thinking can potentially transform today’s roadblocks into tomorrow’s clinical stage agents…

To continue reading our latest highlights on oncology new product development including commentary and analysis BSB subscribers can log-in or you can click to access the content.

This content is restricted to subscribers

Posted by